Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade

Metastatic chondrosarcoma (MCS) has a poor prognosis, and treatment options are scarce in this rare disease. This multicenter observational study provides real-world data on treatment patterns of patients with MCS in France. Treatment characteristics, outcomes in terms of time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients ≥12-year-old treated for a MCS in nine French reference network centers were retrieved from the French Sarcoma Group prospective database. From 2008 to 2018, 127 patients with MCS were included, 31 were metastatic from diagnosis (synchronous cohort), 89 had a metastatic relapse, and 7 had locally advanced unresectable disease, of whom 4 developed secondary metastases (metachronous cohort). Median age at diagnosis was 61 years (14-90), 58.9% of patients received a systemic treatment with a median of 2 lines (1-6), 40.3% had a locoregional procedure on metastasis, and 9.7% of patients participated in a clinical trial at least once in the metastatic setting. Median OS from metastatic diagnosis was 12.7 months [95%CI 8.2, 14.9], without significant difference between the metachronous and synchronous cohorts. Median TTNT was 4.6 months [95%CI 3.0, 5.9], 3.4 months [95%CI 2.7, 4.8], and 3.4 months [95%CI 2.0, 7.9] in first, second, and third lines, respectively. In MCS, benefits of chemotherapies are very limited. Tyrosine kinase inhibitors such as regorafenib or pazopanib show some activity from first line. Locoregional treatment of metastasis is associated with survival and should be proposed when feasible. Inclusion in clinical trials should be prioritized.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2025-07-24
DOI
https://doi.org/10.1002/ijc.70023
Citations
1
Primary Topic
Bone Tumor Diagnosis and Treatments
Type
article
Field-Weighted Citation Impact
1.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade

Mathieu Larroquette, Justine Gantzer, Hélène Bellio, M. Reich et al.
1 citations
International Journal of Cancer
Bone Tumor Diagnosis and Treatments
1.67
article

Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade

Mathieu Larroquette, Justine Gantzer, Hélène Bellio, M. Reich, Pascaline Boudou‐Rouquette, Gregory Cherrier, Max Piffoux, Sixtine De Percin, Carine Bellera, Juliane Berchoud, Simon Nannini, Derek Dinart, Thibaud Valentin, Mehdi Brahmi, Emmanuelle Bompas, Maud Toulmonde, Gonzague de Pinieux, F. Gouin, Axel Le Cesne, Philippe Anract, Bérengère Narciso, Coline Ducrot, M Bonneau
article en
1 citations

Abstract

Metastatic chondrosarcoma (MCS) has a poor prognosis, and treatment options are scarce in this rare disease. This multicenter observational study provides real-world data on treatment patterns of patients with MCS in France. Treatment characteristics, outcomes in terms of time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients ≥12-year-old treated for a MCS in nine French reference network centers were retrieved from the French Sarcoma Group prospective database. From 2008 to 2018, 127 patients with MCS were included, 31 were metastatic from diagnosis (synchronous cohort), 89 had a metastatic relapse, and 7 had locally advanced unresectable disease, of whom 4 developed secondary metastases (metachronous cohort). Median age at diagnosis was 61 years (14-90), 58.9% of patients received a systemic treatment with a median of 2 lines (1-6), 40.3% had a locoregional procedure on metastasis, and 9.7% of patients participated in a clinical trial at least once in the metastatic setting. Median OS from metastatic diagnosis was 12.7 months [95%CI 8.2, 14.9], without significant difference between the metachronous and synchronous cohorts. Median TTNT was 4.6 months [95%CI 3.0, 5.9], 3.4 months [95%CI 2.7, 4.8], and 3.4 months [95%CI 2.0, 7.9] in first, second, and third lines, respectively. In MCS, benefits of chemotherapies are very limited. Tyrosine kinase inhibitors such as regorafenib or pazopanib show some activity from first line. Locoregional treatment of metastasis is associated with survival and should be proposed when feasible. Inclusion in clinical trials should be prioritized.

International Journal of CancerVol. 157(11)
Université de Bordeaux (FR), Inserm (FR), Université Paris Cité (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Nantes (FR), Hôpital Femme Mère Enfant (FR), Institut de Cancérologie Strasbourg (FR), Centre Hospitalier Universitaire de Tours (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Bordeaux Population Health (FR), Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale (FR), Centre de Recherche en Cancérologie de Lyon (FR), Institut Bergonié (FR), Centre d'Investigation Clinique Plurithématique de Bordeaux
Institut National Du Cancer
No poverty
Openalex Percentile: Top 15%
Bone Tumor Diagnosis and Treatments
1.67
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.